KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Invested Capital (2017 - 2025)

Historic Invested Capital for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $2.5 billion.

  • Amneal Pharmaceuticals' Invested Capital rose 708.54% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 708.54%. This contributed to the annual value of $2.3 billion for FY2024, which is 670.65% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Invested Capital stood at $2.5 billion, which was up 708.54% from $2.1 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Invested Capital ranged from a high of $3.1 billion in Q4 2021 and a low of $403.7 million during Q1 2021
  • In the last 5 years, Amneal Pharmaceuticals' Invested Capital had a median value of $2.3 billion in 2024 and averaged $2.1 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first plummeted by 8656.62% in 2021, then skyrocketed by 57228.74% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Invested Capital (Quarter) stood at $3.1 billion in 2021, then fell by 8.83% to $2.8 billion in 2022, then dropped by 13.04% to $2.4 billion in 2023, then decreased by 6.71% to $2.3 billion in 2024, then rose by 8.23% to $2.5 billion in 2025.
  • Its Invested Capital stands at $2.5 billion for Q3 2025, versus $2.1 billion for Q2 2025 and $2.1 billion for Q1 2025.